Show simple item record

dc.contributor.authorElumalai, T
dc.contributor.authorAversa, C.
dc.contributor.authorBuijtenhuijs, B
dc.contributor.authorConroy, Ruth
dc.contributor.authorCroxford, William
dc.contributor.authorDas, A.
dc.contributor.authorDoss, G.
dc.contributor.authorEnting, D.
dc.contributor.authorKitetere, E.
dc.contributor.authorSanderson, B.
dc.contributor.authorVasudev, N.
dc.contributor.authorMistry, H.
dc.contributor.authorChoudhury, Ananya
dc.date.accessioned2020-12-08T05:36:30Z
dc.date.available2020-12-08T05:36:30Z
dc.date.issued2020en
dc.identifier.citationElumalai T, Aversa C, Buijtenhuijs B, Conroy R, Croxford W, Das A, et al. 765P Predicting survival in urothelial cancer patients after immunotherapy using real-world data. Annals of Oncology. 2020;31:S590-S.en
dc.identifier.doi10.1016/j.annonc.2020.08.837en
dc.identifier.urihttp://hdl.handle.net/10541/623484
dc.description.abstractBackground: Metastatic urothelial cancer patients can be treated with immune checkpoint inhibitors (ICIs) in the first- and second-line settings. Real world data is limited. Although there is a survival benefit with second-line ICIs, only 1 in 5 patients experience a durable response. We conducted a multicentre analysis exploring prognostic clinical parameters and their impact on progression-free (PFS) and overall survival (OS). Methods: Between March 2017 and February 2020, data for 208 metastatic urothelial patients treated with single-agent pembrolizumab or atezolizumab were collected retrospectively from 5 centres. PFS was defined as the time from the first date of immunotherapy to disease progression or death from any cause. Clinical parameters such as age, gender, performance status, smoking history, presence of visceral or liver metastasis, haemoglobin level(Hb), lymphocyte count, neutrophil count, lactate dehydrogenase levels (LDH) and PDL-1 status were collected. KaplaneMeier and Cox hazard methods were used for survival analysis. Results: Out of 208 patients, 26(12.5%) received first-line ICIs. Median PFS and OS were 4.5 (range 3.5- 5.7) and 9.2 (range 7.4-10.5) months, respectively. On univariable analysis for OS, liver metastasis, neutrophil count, neutrophil lymphocyte ratio, haemoglobin, and LDH levels were independent prognostic factors. Conclusion: In this large real world data set, we have demonstrated a strong association between OS and known prognostic factors such as liver metastases and Hb level, but interestingly novel factors, neutrophil, and lymphocyte count also. These parameters could be used to create a stratification model, which, if independently validated, could help in selecting patients with urothelial cancer who benefit from ICIs.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2020.08.837en
dc.titlePredicting survival in urothelial cancer patients after immunotherapy using real-world dataen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, Manchester, UK;en
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-12-08T13:24:20Z


Files in this item

Thumbnail
Name:
predicting.pdf
Size:
78.32Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record